NeOnc Technologies Receives Abu Dhabi IND for NEO212; NEO100 Phase 2a Fully Enrolled
NeOnc Technologies Holdings received Investigational New Drug (IND) authorization from the Department of Health – Abu Dhabi for NEO212, its oral perillyl alcohol-temozolomide conjugate for aggressive brain tumors. This marks the first international regulatory clearance for NEO212, establishing a Phase 2 dose of 610 mg and opening a clinical development pathway outside the U.S. Additionally, the company's NEO100 program, targeting IDH1-mutant high-grade glioma, has achieved full enrollment in its Phase 2a study, with interim and top-line data anticipated later in 2026. The CEO has also invested over $500,000 in recent open-market stock purchases, bringing total insider purchases to nearly $1 million over the past year.
Key Highlights
- Abu Dhabi granted IND authorization for NEO212, the first international regulatory clearance.
- NEO212's recommended Phase 2 dose was established at 610 mg after Phase 1 completion.
- NEO100 Phase 2a study for high-grade glioma has achieved full enrollment.
- NEO100 showed tumor remission in approximately 24% of recurrent glioblastoma patients.
- Interim and top-line data for NEO100 are expected later in 2026.
- CEO Amir Heshmatpour invested over $500,000 in recent open-market stock purchases.
- Total insider purchases by the CEO approach $1 million over the past year.
- Company has access to a $75 million at-the-market facility and a $10 million line of credit.
Price Impact
More from NTHI